Legal Defeat Marks Just the Beginning: Meta and Alphabet Face Social Media Addiction Lawsuits with Industry Future Uncertain

Musk Pulls Back the Curtain on Silicon Valley's AI Illusion

S&P 500 Eminis Slip 0.7%, Nasdaq Futures Down 0.9% as Oil Climbs More Than 3%

MU vs. NVDA vs. AMD: Which Chip Stock Has the Best Upside Potential, According to Wall Street?

S&P 500 Eminis Resume Trading Down 0.5%, Nasdaq Futures Fall 0.6%

Spring Pruning Timely Ensures Bountiful Harvest Prospects

Genuine Care Fosters Collective Endeavor: The Story of Ding Lan, Deputy Party Secretary and Mayor of Mashenqiao Town, Jizhou District, Tianjin

Silicon Valley Has Stopped Talking Politics -- Except for This Google Executive -- WSJ

Merck announces data from Phase 2 Cadence trial of Winrevair

BRIEF-Merck & Co Inc Says Winrevair Meets Primary Endpoint In Phase 2 Cadence Trial

Merck says Phase 2 CADENCE shows WINREVAIR cuts PVR in CpcPH-HFpEF

Merck & Co Inc - Winrevair to Advance Into Registrational Phase 3 Program in Cpcph-Hfpef

Positive Data From Phase 2 Cadence Trial Provides Definitive Proof-of-Concept for Winrevair™ (Sotatercept-Csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck & Co: Totality of Evidence Across Hemodynamic, Functional, Echocardiographic and Clinical Endpoints Supports Advancing Development of Winrevair

J&J announces new long-term 52-week data from Phase 3 Iconic-Advance 1, 2